Antipsychotic Drugs Market (2025 - 2033) Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts

Antipsychotic Drugs Market Summary

Antipsychotic medications, also known as neuroleptics, are commonly employed to alleviate symptoms linked to psychosis. Antipsychotic medications can effectively decrease and manage various symptoms, such as paranoia and auditory hallucinations, including delusions and hearing voices. Antipsychotic medications work by inhibiting the activity of dopamine and other neurotransmitters in the brain. First and second-generation antipsychotic medications are currently available in the market.

The increasing prevalence of psychotic disorders is expected to drive the demand in the antipsychotic drugs industry. The Schizophrenia burden consistently affects men more than women, and as life expectancy improves regionally, the overall burden of Schizophrenia is expected to grow further. Aging populations also support demand, as conditions such as dementia-related psychosis become more prevalent. Market growth has been reinforced by regulatory approvals of new formulations and novel mechanisms of action, which address limitations of older therapies.

Advancements in technology and research in drug development have also resulted in the creation of newer and more efficient Antipsychotic drugs. Pharmaceutical companies are investing significantly in researching and developing medications with fewer side effects, higher effectiveness, and enhanced patient adherence. In September 2025, H. Lundbeck A/S and Otsuka Holdings Co., Ltd received a Complete Response Letter (CRL) from the FDA for a supplemental New Drug Application (NDA) for REXULTI (brexpiprazole) in combination with sertraline for treating adults with PTSD.

In January 2023, Eisai Co., Ltd. obtained FDA approval for Leqembi through the Accelerated Approval Pathway for Alzheimer's disease treatment. The introduction of advanced pharmaceutical choices for neurological disorders is increasing the use of antipsychotic drugs among patients worldwide.

Disease Insights

Schizophrenia accounted for the largest market revenue share of 39.0% in 2024. Schizophrenia is a serious mental illness that impacts a significant number of individuals worldwide. According to the World Health Organization (WHO), Schizophrenia affects approximately 23 million people worldwide, equating to about 1 in 345 individuals. This disorder often manifests in late adolescence or early adulthood and is a leading cause of disability. Individuals with Schizophrenia typically experience a life expectancy that is 9 years shorter than the general population. The rising occurrence of Schizophrenia and related conditions and an increasing proportion of elderly individuals who are at a higher risk for developing late-onset Schizophrenia are expected to drive the segmental growth. Expanding awareness, improved diagnostic capabilities, and growing access to mental health services in emerging markets are likely to boost demand for antipsychotic therapies further.

Bipolar disorder is expected to register the fastest CAGR of 7.1% during the forecast period. The disorder significantly contributes to the global burden of disease, with affected individuals facing increased risk of suicide and substantial functional impairment. Medications and therapies for bipolar disorder are used to control symptoms of the illness. These medicines help stabilize emotions, decrease the intensity and frequency of mood changes, and enhance the overall well-being of those affected. The medications for bipolar disorder include haloperidol, olanzapine, quetiapine, and risperidone.

Drug Insights

Aripiprazole accounted for the largest revenue share of the antipsychotic drugs market in 2024. The adoption of third-generation products drives the sales in this segment. Furthermore, it is anticipated that product approvals are expected to experience the most significant growth during the projected period. In April 2025, Mezofy (aripiprazole) received FDA approval as an oral film formulation for treating schizophrenia in adults and patients aged 13 years and older.

The Brexpiprazole segment is expected to register the fastest CAGR during the forecast period. Brexpiprazole is a medication that alters serotonin and dopamine activity. It is used as an add-on treatment for major depressive disorder, Schizophrenia, and agitation linked to Alzheimer's disease.

Therapeutic Class Insights

The second-generation therapeutic class accounted for the largest revenue share of the antipsychotic drugs industry in 2024. The growth of this segment can be attributed to the presence of several second-generation medications available in the market, such as HAFYERA, INVEGA, SEROQUEL, XR, ZYPREXA, and others. Furthermore, the market's growth is expected to be propelled by the enhanced efficiency and safety of the drugs in this generation.

The third generation is expected to register the fastest CAGR during the forecast period. Increasing advancements in drug development methods are a major factor driving growth in the market. For instance, according to the study published by the National Library of Medicine in February 2024, the development of molecules that act as partial agonists and dopaminergic receptors in treating psychosis has led to the development of new and advanced drugs. This innovation has led to third-generation antipsychotics, which include medications such as aripiprazole, brexpiprazole, lurasidone, and cariprazine.

Distribution Channel Insights

The retail pharmacies segment dominated the market and accounted for the largest share in 2024. Retail pharmacies are easily available to patients and often act as the initial point of contact for individuals requiring prescription medications. Retail pharmacies carry a wide selection of antipsychotic drugs to meet the needs of individuals with different mental health disorders. They offer advice and support to patients regarding how to use medications and potential side effects, which helps increase their popularity. Many patients prefer retail pharmacies for antipsychotic medication due to their convenience, especially for long-term therapy.

Online pharmacies are projected to grow at the fastest CAGR over the forecast period by providing more patient convenience and easy access to medication. Online pharmacy platforms now offer features like e-prescriptions, doorstep delivery, and real-time medication tracking, ensuring timely access to essential treatments. Additionally, many online pharmacies provide 24/7 customer support and maintain strict quality control measures, including partnerships with licensed pharmacists, to ensure the authenticity and safety of medications.

Regional Insights

North America dominated the antipsychotic drugs market with the largest revenue share of 37.6% in 2024. Some of the critical factors attributable to the region’s market dominance include the strong prevalence of psychiatric illnesses in the region and the market presence of prominent biopharmaceutical companies. According to the 2024 American Psychiatric Association poll, 43% of U.S. adults reported feeling more anxious than the previous year, up from 37% in 2023. According to the National Institute of Health (NIH), approximately 57.8 million individuals in the U.S. had a mental illness in 2021. This high prevalence of mental illnesses will likely drive market growth in the region. Other contributive factors include the strong adoption of antipsychotics and technological superiority in the region.

U.S. Antipsychotic Drugs Market Trends

The U.S. antipsychotic drugs industry accounted for the largest revenue share of 89.5% in 2024 due to high rates of mental illnesses such as Schizophrenia and bipolar disorder in the country. In addition, there is significant healthcare spending, including extensive insurance coverage for mental health services. For instance, according to the article published by The White House in May 2022, the U.S. Federal Government covers some costs related to mental health disorder treatments and spent approximately USD 280 billion on mental health services in 2020. The spending on mental health services can help improve people’s access to quality mental health facilities, which is likely to drive market growth.

Europe Antipsychotic Drugs Market Trends

Europe's antipsychotic drugs industry is identified as a lucrative region. According to the WHO, more than 150 million people in Europe lived with a mental health condition in 2021, and only one in three people with depression received the care they needed. The increasing number of patients with mental disorders and the need for treatment options are key drivers of the market growth. The steady growth of the market is driven by the increasing awareness of mental health disorders, rising prevalence of conditions such as schizophrenia and bipolar disorder, and improvements in healthcare infrastructure. Moreover, digital health solutions and online pharmacy services enhance accessibility, making treatments more convenient for patients and supporting overall market growth.

Asia Pacific Antipsychotic Drugs Market Trends

The Asia Pacific antipsychotic drugs industry is expected to witness the fastest growth over the forecast period, due to a large portion of the population experiencing chronic and mental illnesses. Increasing indications, strong healthcare spending, and growing investments in healthcare infrastructure are the main factors fueling the demand for antipsychotic drugs in the region. The increasing efforts by government and private players to increase mental health awareness are further expected to drive growth in the region.

China's antipsychotic drugs market is expected to grow rapidly in the coming years due to the high prevalence of mental illnesses and efforts by authorities to create awareness and improve access to treatments. For instance, according to the WHO, approximately 41 million people in China suffer from depression. In addition, at least 80% of primary and secondary schools are expected to be equipped with mental health personnel by 2022, according to Healthy China targets. Such initiatives are expected to add growth to the market.

Latin America Antipsychotic Drugs Market & Trends

Latin America's antipsychotic drugs industry is expected to witness growth due to the systemic gaps in mental health care access and quality, and ongoing policy and clinical initiatives. However, government initiatives, such as intersectoral coordination and collaborations between emergency mental health and psychosocial support stakeholders in Brazil, are expected to help increase awareness and access to treatment in the region and drive market growth.

The antipsychotic drugs market in Argentina is likely to witness significant growth over the forecast period, owing to the rising prevalence of mental health disorders and subsequent government efforts to increase related awareness. For instance, in 2022, Argentina collaborated with the WHO for the Director General's Special Initiative for Mental Health. It is expected to help scale up mental health services, increase access, and improve coverage of about 5.2 million Argentinians by creating community-based services and strengthening secondary-level mental health services. These efforts made by the government would help people become aware of mental health, its medications, and drugs for treatment, and help the market grow over the forecast period.

MEA Antipsychotic Drugs Market & Trends

The MEA antipsychotic drugs industry is to witness significant growth in the coming years. Although it accounts for a limited market share, the current increased healthcare expenditures and awareness initiatives in this region are driving the growth in the antipsychotic market. For instance, the South African CDC launched the Mental Health Leadership Programme, which is expected to create awareness among people regarding mental health disorders.

South Africa's antipsychotic drugs market is anticipated to witness significant growth over the forecast period, due to the high prevalence of mental illnesses in the country. According to a report of Mental State of the World in 2023 report released by Sapien Labs, South Africa had the highest percentage of people with mental health disorders out of 64 countries. Various collaborations and efforts by the government to create awareness regarding mental health and treatment in the country are also expected to add to the market growth. For instance, in 2023, the South African government, for the first time, collaborated with mental health professionals to host a conference dedicated to mental health.

Key Antipsychotic Drugs Company Insights

Some of the key companies in the antipsychotic drugs market include H. Lundbeck A/S; Otsuka Pharmaceutical Co., Ltd.; Janssen Pharmaceuticals, Inc.; and Eli Lilly and Company.

• Teva Pharmaceutical Industries Ltd. is a pharmaceutical company that focuses mainly on producing generic drugs. It also has business endeavors in branded drugs, active pharmaceutical ingredients (APIs), contract manufacturing services, and an out-licensing platform. The company develops drugs for multiple medical areas, including psychiatry, oncology, and respiratory.

• Alkermes is a biopharmaceutical company that specializes in creating medications for psychiatric and neurological conditions. Alkermes has received approval for four of its own commercial drug products, which are used to treat Schizophrenia, bipolar I disorder, alcohol dependence, and opioid dependence.

Recent Developments

• In September 2024, Bristol Myers Squibb announced that the U.S. FDA approval of COBENFY (xanomeline and trospium chloride), a first-in-class oral medication for treating Schizophrenia in adults.

• In April 2024, Alkermes presented clinical data at the 2024 Congress of the Schizophrenia International Research Society (SIRS) from a phase 3 extension study. It aimed to assess the impact of the safety, durability, tolerability, and effectiveness of their antipsychotic drug, LYBALVI.

• In March 2024, Otsuka Pharmaceutical Co., Ltd announced that H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Europe Ltd announced the EC approval of Abilify Maintena 720mg/960mg (aripiprazole) for maintenance treatment of schizophrenia.

• In May 2024, Otsuka Pharmaceutical Co., Ltd. reported that its U.S. branch, OPDC, and Lundbeck shared results from the Phase II (Trial 061) and Phase III trials (Trial 071 and 072) on the safety and effectiveness of brexpiprazole with sertraline for treating PTSD in adults. The results were presented at the ASCP annual meeting in Miami.

• In October 2022, Lupin announced the launch of Paliperidone extended tablets, which are used in the treatment of mental disorders.

Antipsychotic Drugs Market Report Scope

Global Antipsychotic Drugs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antipsychotic drugs market report based on disease, drug, therapeutic class, distribution channel, and region:

• Disease Outlook (Revenue, USD Million, 2021 - 2033)

  • Schizophrenia

  • Bipolar Disorder

  • Unipolar Depression

  • Dementia

  • Others

• Drug Outlook (Revenue, USD Million, 2021 - 2033)

  • Risperidone

  • Quetiapine

  • Olanzapine

  • Aripiprazole

  • Brexpiprazole

  • Paliperidone Palmitate

  • Others

• Therapeutic Class Outlook (Revenue, USD Million, 2021 - 2033)

  • First Generation

  • Second Generation

  • Third Generation

• Distribution Channel Class Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait